BioPharma Resources

Drug Trial Radar · NCT07851246

A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age

A Phase 3 Randomized, Observer-Blind, Controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of an mRNA-based Seasonal Influenza Vaccine, in Adults 18-64 Years of Age

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Jul 9, 2027

Study completion Jul 9, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial will study an investigational seasonal influenza vaccine in adults 18 to 64 years of age. The vaccine is based on messenger ribonucleic acid, also called mRNA. The main goals of the study are to learn how well the vaccine helps the body make an immune response against influenza and what medical problems participants may have after vaccination. Researchers will also compare immune responses in adults 18 to 64 years of age from this study, with immune responses in adults 65 years of age and older from another study. Participants will receive 1 injection into the upper arm muscle and will be followed for about 6 months.

Conditions

  • Influenza, Human

Interventions

  • mRNA Seasonal Flu vaccineBiological

    One dose of the mRNA Flu vaccine received intramuscularly.

  • Comparator 1Biological

    One dose of the comparator vaccine received intramuscularly.

  • Comparator 2Biological

    One dose of the comparator vaccine received intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Titer (GMT) of Antigen 1 TiterTime frame: At Day 29
  2. GMT of Antigen 2 TiterTime frame: At Day 29
  3. Percentage of participants with Antigen 1 seroconversion rate (SCR)Time frame: From Day 1 to Day 29
  4. Number of participants with solicited administration site adverse eventsTime frame: Day 1 to Day 7
  5. Number of participants with systemic adverse eventsTime frame: Day 1 to Day 7
  6. Number of participants with unsolicited adverse eventsTime frame: Day 1 to Day 28
  7. Number of participants with serious adverse events (SAEs)Time frame: Day 1 to Day 181
  8. Number of participants with adverse events of special interest (AESIs)Time frame: Day 1 to Day 181
  9. Number of Participants with any Laboratory abnormalitiesTime frame: At Day 1 (pre-dose) and at Day 29 (post - dose)

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Glendale, Arizona · Recruiting

  • GSK Investigational Site

    Tucson, Arizona · Recruiting

  • GSK Investigational Site

    San Diego, California · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami Lakes, Florida · Recruiting

  • GSK Investigational Site

    Meridian, Idaho · Recruiting

  • GSK Investigational Site

    Valparaiso, Indiana · Recruiting

  • GSK Investigational Site

    Lenexa, Kansas · Recruiting

  • GSK Investigational Site

    Hartsdale, New York · Recruiting

  • GSK Investigational Site

    Spartanburg, South Carolina · Recruiting

  • GSK Investigational Site

    DeSoto, Texas · Recruiting

  • GSK Investigational Site

    Fort Worth, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.